Novo Rapid (Insulin Aspart) is an insulin analog produced by recombinant DNA technology, it is chemically identical to human insulin except that the amino acid Proline has been substituted for aspartic acid at position B28 of the insulin molecule. This gives Novo Rapid a much more rapid onset of action and a shorter duration of action than regular insulin.
Regular Insulin has an onset of action about 1 hour after injection and the effect peaks in 4 hours and lasts 6 hours.
Novo Rapid (Insulin Aspart) has an onset of action about 30 minutes after injection and a peak effect at 1 hour with essentially no effect 3 hours after injection.
Blood glucose starts to rise less than 30 minutes after a meal, thus Novo Rapid is able to deal with this glucose rise earlier than Regular Insulin. As expected, there is less hyperglycemia 1 or 2 hours after a meal than there is using Regular Insulin and there is less hypoglycemia 3 to 4 hours after a meal than with Regular Insulin. In other words the action of Novo Rapid is closer to the action of food and it is therefore an effective insulin to take with meals.
Novo Rapid may be used in Intensive Insulin Treatment Routines in which Insulin is given with each meal and it may also be used in an insulin pump. It is supplied in 10 ml Vials for administration with a syringe or 3 ml cartridges for use in the Novolin Pen* 3, the Novolin Pen* Junior, the Induo* and the Innovo* insulin delivery devices supplied by Novo Nordisk Canada Inc.